MedInnovation
Konstantin C. has work experience as a Chief Executive Officer at Medinnovation since April 2013, and at ESPIRE Technologies Gmbh, where they held the position of CEO starting from May 2017.
Konstantin C.'s education history includes studying Management at the State University of Management (SUM) and Computer and Information Sciences at Yuzhno-Uralskiy Gosudarstvennyy Universitet (YURGU). The specific degree names and start/end years for both programs are not provided.
This person is not in any teams
MedInnovation
MedInnovation has developed a new diagnostic platform called Albumin Functionality Test (AFT). The platform allows to detect a number of severe diseases like cancer, liver disorders (cirrhosis) and sepsis at the early stage. AFT is based on Electron Spin Resonance Spectroscopy technique providing physicians with a fast, non-invasive and reliableroutine laboratory blood test. AFT is the only test to determine the functional characteristics of human serum albumin (HSA) - main transport protein in the blood system. The platform allows to obtain 45 independent biophysical parameters of albumin for further analyses. It opens a great perspective for AFT as a potential backbone diagnostic technology. MedInnovation has competed development of full set of instruments including digital ESR-Analyzer, Automated Liquid Handling System, Software, Data Base and Reagent Kits. Having promising results from a number of POC and phase II clinical trials the company is on the way to validate the test in the US and Europe. Medinnovation is TÜV-certified producer of medical devices according to DIN EN 13485:2016